Bernard Gilly, GenSight CEO (Eric Piermont/AFP via Getty Images)
June 30, 2021 07:37 AM EDTUpdated 11:00 AM
R&D
Cell/Gene Tx

Gen­Sight's gene ther­a­py mys­tery con­tin­ues, as pa­tients im­prove in an­oth­er failed tri­al

Jason Mast

Editor

A three-year-old med­ical mys­tery took its lat­est turn Thurs­day, when Gen­Sight re­leased da­ta from its third tri­al for a rare form of blind­ness: Once again …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

Ab­b­Vie dou­bles down on siR­NA with $335M up­front bet on ADARx

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

SK, Car­lyle bol­ster blue­bird bio bid; Theri­ni Bio rais­es $39M

Lack of de­tail in Trump's drug price plan rais­es more ques­tions than an­swers

Ad­vo­ca­cy groups and ex­perts call for decade-long ban on germline edit­ing

A service from the Financial Times